Scholar Rock Holding (SRRK) Notes Payables (2021 - 2024)
Scholar Rock Holding (SRRK) recorded quarterly Notes Payables of $1.6 million in Q2 2024, down 71.13% quarter-over-quarter from $5.5 million in Q1 2024.
Scholar Rock Holding (SRRK) Notes Payables (2021 - 2024) Analysis & Trends
Scholar Rock Holding's Notes Payables history runs 4 years deep, the most recent figure standing at $1.6 million for Q2 2024.
- In Q2 2024, Notes Payables changed N/A year-over-year to $1.6 million; the TTM figure through Jun 2024 stood at $1.6 million (changed N/A YoY), while the FY2023 annual figure was $1.3 million, changed N/A from the prior year.
- Notes Payables was $1.6 million for Q2 2024 at Scholar Rock Holding, down from $5.5 million in the prior quarter.
- In the past five years, Notes Payables ranged from a high of $11.6 million in Q2 2022 to a low of $805000.0 in Q3 2022.
- Historically, Notes Payables has averaged $4.1 million across 4 years, with a median of $1.6 million in 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Scholar Rock Holding | 6.03 Bn | 5.55 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 1.59 Mn |
| Mar 31, 2024 | 5.50 Mn |
| Dec 31, 2023 | 1.33 Mn |
| Sep 30, 2022 | 805,000.00 |
| Jun 30, 2022 | 11.58 Mn |
| Mar 31, 2022 | 6.58 Mn |
| Dec 31, 2021 | 1.58 Mn |